Schrodinger Inc stock (US80655G1067): shares steady after May gains on Nasdaq

Schrodinger Inc shares on Nasdaq traded broadly stable on 05/28/2026 after a solid performance in May, keeping the United States-based drug discovery software and biotech group on the radar of investors watching healthcare and technology names.

Schrodinger Inc shares traded broadly unchanged on Nasdaq on 05/28/2026, with investors consolidating recent gains after the United States-based group appeared among notable monthly performers in May, underscoring ongoing interest in its mix of drug discovery software and therapeutics development, according to data from US market platforms as of 05/28/2026.

The stock, listed on Nasdaq under the ticker SDGR, changed hands around the low-teens USD range in late May 2026, following a May performance that market statistics services ranked among visible gainers in the healthcare space, with one monthly screen citing a rise of just over 6% and a market capitalization of close to USD 1 billion as of late May 2026, according to StockTitan data as of 05/27/2026.

Based in the United States and traded in USD, Schrodinger Inc remains part of the broader US healthcare and technology ecosystem, where names combining computational platforms with biotech pipelines have drawn attention as investors assess prospects for software-enabled drug design tools and partnered programs with larger pharmaceutical companies.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: SDGR
• Sector/industry: Computational drug discovery software and biotechnology
• Headquarters/country: New York, United States
• Core markets: United States, Europe, Asia-Pacific biopharmaceutical and research customers
• Key revenue drivers: Software licensing and subscriptions, drug discovery collaborations, milestone and royalty income
• Home exchange/listing venue: Nasdaq (SDGR)
• Trading currency: USD

Schrodinger Inc: core business model

Schrodinger Inc runs a dual business that combines physics-based computational software for molecular design with an internal and partnered drug discovery pipeline, generating revenue primarily from software licenses and collaborative discovery economics with pharmaceutical and biotech clients.

Industry trends and competitive position

Schrodinger Inc operates at the intersection of life sciences and high-performance computing, a niche within the United States and global healthcare sector where demand for in silico design tools has been driven by the need to shorten discovery timelines and improve hit-to-lead efficiency, as highlighted by multiple industry research providers tracking pharma R&D productivity over the past few years.

Within this environment, the company competes with both specialized molecular modeling software vendors and large scientific computing platforms, while also facing competition from traditional wet-lab discovery approaches, and its positioning depends on the performance of its platform in external benchmarks, the ability to secure or extend collaboration agreements with larger pharmaceutical companies, and the progress of its own pipeline assets into later-stage trials, which together influence investor perception of its long-term role in the US healthcare technology landscape.

Conclusion

The broadly stable trading in Schrodinger Inc on Nasdaq on 05/28/2026 follows a period of measurable gains in May, keeping the United States-based stock in focus for investors watching healthcare technology names and software-enabled drug discovery platforms.

Against the backdrop of a sector that is steadily adopting computational tools to streamline R&D, the company’s position within the US market will depend on its ability to translate platform usage and collaborations into recurring software revenue and meaningful progress in its discovery programs.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.